002422 科伦药业
已收盘 04-15 15:00:00
资讯
新帖
简况
科伦药业:公司出于战略目的而计划长期持有海南普利制药股份有限公司股权
证券之星 · 04-15 17:39
科伦药业:公司出于战略目的而计划长期持有海南普利制药股份有限公司股权
股市必读:科伦药业(002422)4月13日董秘有最新回复
证券之星 · 04-14 00:57
股市必读:科伦药业(002422)4月13日董秘有最新回复
4月9日科伦药业发布公告,股东减持318.21万股
证券之星 · 04-09
4月9日科伦药业发布公告,股东减持318.21万股
科伦药业2025年业绩全面遇冷:增长失速、主业承压,创新转型何时破局?
新浪证券 · 04-09
科伦药业2025年业绩全面遇冷:增长失速、主业承压,创新转型何时破局?
【机构调研记录】长江证券调研科伦药业、伟星新材等7只个股(附名单)
证券之星 · 04-08
【机构调研记录】长江证券调研科伦药业、伟星新材等7只个股(附名单)
东吴证券:给予科伦药业买入评级
证券之星 · 04-07
东吴证券:给予科伦药业买入评级
科伦药业(002422)2025年年报简析:净利润同比下降42.03%
证券之星 · 04-04
科伦药业(002422)2025年年报简析:净利润同比下降42.03%
科伦药业最新公告:2025年度净利润17.02亿元同比下降42.03%
证券之星 · 04-02
科伦药业最新公告:2025年度净利润17.02亿元同比下降42.03%
科伦药业最新公告:子公司SKB103新药临床试验获NMPA批准
证券之星 · 03-24
科伦药业最新公告:子公司SKB103新药临床试验获NMPA批准
科伦药业(002422.SZ):注射用阿立哌唑获药品注册批准
智通财经 · 03-20
科伦药业(002422.SZ):注射用阿立哌唑获药品注册批准
科伦药业(002422.SZ):布瑞哌唑口溶膜获药品注册批准
智通财经 · 03-20
科伦药业(002422.SZ):布瑞哌唑口溶膜获药品注册批准
科伦药业(002422 .SZ):芦康沙妥珠单抗(sac-TMT)于2025年欧洲肺癌大会上公布研究成果
智通财经 · 03-18
科伦药业(002422 .SZ):芦康沙妥珠单抗(sac-TMT)于2025年欧洲肺癌大会上公布研究成果
科伦药业(002422)披露子公司芦康沙妥珠单抗OptiTROP-Lung03研究OS最终分析结果,3月18日股价上涨0.42%
证券之星 · 03-18
科伦药业(002422)披露子公司芦康沙妥珠单抗OptiTROP-Lung03研究OS最终分析结果,3月18日股价上涨0.42%
英硅智能与Liquid AI达成合作;氢溴酸他泽司他片被召回
21世纪经济报道 · 03-10
英硅智能与Liquid AI达成合作;氢溴酸他泽司他片被召回
科伦药业(002422.SZ):SKB575新药临床试验申请获批准
智通财经 · 03-09
科伦药业(002422.SZ):SKB575新药临床试验申请获批准
3月6日科伦药业涨7.93%,中欧医疗健康混合A基金重仓该股
证券之星 · 03-06
3月6日科伦药业涨7.93%,中欧医疗健康混合A基金重仓该股
股市必读:科伦药业(002422)3月4日董秘有最新回复
证券之星 · 03-05
股市必读:科伦药业(002422)3月4日董秘有最新回复
科伦药业(002422)发布关于首次回购公司股份的公告,3月2日股价下跌1.11%
证券之星 · 03-02
科伦药业(002422)发布关于首次回购公司股份的公告,3月2日股价下跌1.11%
股市必读:科伦药业(002422)2月25日董秘有最新回复
证券之星 · 02-26
股市必读:科伦药业(002422)2月25日董秘有最新回复
科伦药业(002422)披露回购公司股份进展公告,2月3日股价上涨0.86%
证券之星 · 02-03
科伦药业(002422)披露回购公司股份进展公告,2月3日股价上涨0.86%
加载更多
公司概况
公司名称:
四川科伦药业股份有限公司
所属行业:
医药制造业
上市日期:
2010-06-03
主营业务:
四川科伦药业股份有限公司的主营业务是输液产品及非输液医药产品的研发、生产和销售。公司的主要产品是大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等。公司是国家大容量注射剂工程技术研究中心、生物靶向药物国家工程研究中心等多个国家创新平台。
发行价格:
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":35.7,"timestamp":1776236631000,"preClose":34.29,"halted":0,"volume":33941387,"delay":0,"changeRate":0.0411,"floatShares":1306000000,"shares":1598000000,"eps":0.2929,"marketStatus":"已收盘","change":1.41,"latestTime":"04-15 15:00:00","open":34.66,"high":35.79,"low":34.11,"amount":1192000000,"amplitude":0.049,"askPrice":35.71,"askSize":70,"bidPrice":35.7,"bidSize":1289,"shortable":0,"etf":0,"ttmEps":0.2929,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"adjPreClose":34.29,"symbolType":"stock","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":37.72,"lowLimit":30.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.26,"roa":"--","peRate":121.884602,"roe":"7.24%","epsLYR":1.07,"committee":0.452088,"marketValue":57051000000,"turnoverRate":0.026,"status":0,"floatMarketCap":46620000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"2627288322","title":"科伦药业:公司出于战略目的而计划长期持有海南普利制药股份有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2627288322","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627288322?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:39","pubTimestamp":1776245949,"startTime":"0","endTime":"0","summary":"证券之星消息,科伦药业(002422)04月15日在投资者关系平台上答复投资者关心的问题。投资者提问:贵司持有2000多万的普利制药,都已经退市了 ,为什么还高位买进科伦药业回复:投资者您好,公司出于战略目的而计划长期持有海南普利制药股份有限公司股权。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK1574","BK1191","LU1934453819.USD","LU1064131003.USD","BK0060","LU1979443071.USD","LU1064130708.USD","002422","BK0239","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627145741","title":"股市必读:科伦药业(002422)4月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2627145741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627145741?lang=zh_cn&edition=full","pubTime":"2026-04-14 00:57","pubTimestamp":1776099429,"startTime":"0","endTime":"0","summary":"截至2026年4月13日收盘,科伦药业报收于34.67元,上涨1.97%,换手率1.46%,成交量19.01万手,成交额6.57亿元。科伦有能力研发出好的产品但不会卖也没用啊董秘: 投资者您好,感谢您对公司的关注与建议。当日关注点来自交易信息汇总:4月13日主力资金净流入97.76万元,游资积极介入,散户资金呈净流出态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400000733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0060","BK0239","LU1064131003.USD","LU1934453819.USD","002422","LU1979443071.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626184545","title":"4月9日科伦药业发布公告,股东减持318.21万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626184545","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626184545?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:01","pubTimestamp":1775736112,"startTime":"0","endTime":"0","summary":"证券之星消息,4月9日科伦药业发布公告《科伦药业:关于持股5%以上股东减持股份触及1%整数倍的公告》,其股东雅安市国有资产经营有限责任公司于2026年3月10日至2026年4月8日间合计减持318.21万股,占公司目前总股本的0.1991%,变动期间该股股价上涨8.56%,截止4月8日收盘报34.63元。股东增减持详情见下表:根据科伦药业2025年年报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900034357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0060","BK0239","LU1064131003.USD","LU1934453819.USD","002422","LU1979443071.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626901599","title":"科伦药业2025年业绩全面遇冷:增长失速、主业承压,创新转型何时破局?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626901599","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626901599?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:29","pubTimestamp":1775719740,"startTime":"0","endTime":"0","summary":" 近日,科伦药业披露2025年年度报告。作为国内输液与抗生素中间体龙头,科伦药业2025年的经营态势却较为严峻,传统业务稳健托底、创新业务逐步蓄力的增长逻辑正面临挑战。从财务数据看,公司营收、净利润双双大幅下滑,盈利指标持续恶化,现金流同步缩水,多重风险集中显现。 2025年,科伦药业核心财务指标全线转向。 综上,2025年是科伦药业压力集中释放的一年。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-04-09/doc-inhtwtex8839730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2148510915.USD","002422","BK0239","LU1934453819.USD","BK0060","LU1979443071.USD","LU1064130708.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625967464","title":"【机构调研记录】长江证券调研科伦药业、伟星新材等7只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625967464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625967464?lang=zh_cn&edition=full","pubTime":"2026-04-08 08:09","pubTimestamp":1775606971,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月7日披露的机构调研信息,长江证券近期对7家上市公司进行了调研。2)伟星新材 调研纪要:2025年公司实现营业收入53.82亿元,同比下降14.12%;归母净利润7.41亿元,同比下降22.24%;主营业务毛利率41.14%。投资收益下降因金融资产公允价值变动及理财收益减少。2025年第四季度经营业绩环比变化的主要原因是四季度研发费用增加以及计提年终考核奖励等致管理费用增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800004612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002372","LU1064131003.USD","BK0185","LU2460026573.USD","000783","BK0183","BK0276","BK0050","BK0028","BK0197","LU1064130708.USD","IE0005HP3H50.USD","LU2148510915.USD","002422","BK0220","BK0060","LU1934453819.USD","LU1979443071.USD","BK0188","BK0201","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625355936","title":"东吴证券:给予科伦药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2625355936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625355936?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:07","pubTimestamp":1775552848,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对科伦药业进行研究并发布了研究报告《2025年年报点评:业绩短期承压,创新转型驱动长期价值不变》,给予科伦药业买入评级。最新盈利预测明细如下:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为44.96。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700023657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624662296","title":"科伦药业(002422)2025年年报简析:净利润同比下降42.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624662296","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624662296?lang=zh_cn&edition=full","pubTime":"2026-04-04 06:05","pubTimestamp":1775253958,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期科伦药业发布2025年年报。根据财报显示,科伦药业净利润同比下降42.03%。截至本报告期末,公司营业总收入185.13亿元,同比下降15.13%,归母净利润17.02亿元,同比下降42.03%。按单季度数据看,第四季度营业总收入52.36亿元,同比上升4.23%,第四季度归母净利润5.01亿元,同比上升7.81%。该数据低于大多数分析师的预期,此前分析师普遍预期2025年净利润为盈利27.13亿元左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040400002633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501106","title":"科伦药业最新公告:2025年度净利润17.02亿元同比下降42.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501106","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624501106?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:00","pubTimestamp":1775134844,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称,公司发布2025年年度报告,实现营业收入185.13亿元,同比下降15.13%;归属于上市公司股东的净利润为17.02亿元,同比下降42.03%。公司计划向全体股东每10股派发现金红利4.68元(含税),不送红股,不以公积金转增股本。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200039961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068155","title":"科伦药业最新公告:子公司SKB103新药临床试验获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068155","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621068155?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:30","pubTimestamp":1774344633,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称,公司控股子公司科伦博泰自主研发的双特异性抗体偶联药物(bsADC)SKB103的新药临床试验(IND)申请已获国家药品监督管理局药品审评中心批准,用于治疗晚期实体瘤。SKB103是科伦博泰首个进入临床阶段的TAA-PD-L1 bsADC,也是其第二款进入临床的肿瘤治疗bsADC。该药物基于OptiDC平台开发,在临床前研究中展现出优异的抗肿瘤活性和安全性。公司提示,创新药研发存在不确定性,后续进展将及时披露。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400029666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064130708.USD","002422","LU1934453819.USD","LU1979443071.USD","LU2148510915.USD","LU1064131003.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786554","title":"科伦药业(002422.SZ):注射用阿立哌唑获药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786554","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786554?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:23","pubTimestamp":1773995000,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦药业(002422.SZ)公告,公司子公司湖南科伦制药有限公司的化学药品“注射用阿立哌唑”于近日获得国家药品监督管理局的药品注册批准。阿立哌唑为第二代非典型抗精神病药,是全球首个获批的多巴胺D2受体部分激动剂及多巴胺系统稳定剂,能同时缓解阳性和阴性症状,且锥体外系和体重增长等不良反应较轻,为国内外临床最常使用的抗精神病药物之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦药业(002422.SZ):注射用阿立哌唑获药品注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1064131003.USD","LU1934453819.USD","BK0239","LU1064130708.USD","002422","LU1979443071.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786395","title":"科伦药业(002422.SZ):布瑞哌唑口溶膜获药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786395","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786395?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:19","pubTimestamp":1773994781,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦药业(002422.SZ)公告,公司的化学药品“布瑞哌唑口溶膜”于近日获得国家药品监督管理局的药品注册批准。布瑞哌唑为第二代非典型抗精神病药,因对多巴胺和5-羟色胺系统的平衡调节,可兼顾疗效与安全性,是全球唯一全部副作用风险均与安慰剂无显著差异的口服抗精神病药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1064131003.USD","LU1064130708.USD","002422","LU1979443071.USD","LU1934453819.USD","LU2148510915.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620551252","title":"科伦药业(002422 .SZ):芦康沙妥珠单抗(sac-TMT)于2025年欧洲肺癌大会上公布研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2620551252","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620551252?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:22","pubTimestamp":1773843743,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦药业(002422 .SZ)公告,公司控股子公司四川科伦博泰生物医药股份有限公司(简称“科伦博泰”)靶向人滋养细胞表面抗原2(TROP2)抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT)(佳泰莱®) 关键临床研究(OptiTROP-Lung03)的总生存期(OS)最终分析结果将于当地时间3 月25日至28日在丹麦哥本哈根举行的2026年欧洲肺癌大会(ELCC)的小型口头报告专场公布。该研究成果成功入选突破性摘要 (报告编号:LBA4),相关摘要发布于ESMOOPEN期刊。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","BK0060","BK0239","LU1064130708.USD","002422","LU2148510915.USD","LU1979443071.USD","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825236","title":"科伦药业(002422)披露子公司芦康沙妥珠单抗OptiTROP-Lung03研究OS最终分析结果,3月18日股价上涨0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825236","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620825236?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:19","pubTimestamp":1773843555,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘,科伦药业报收于33.34元,较前一交易日上涨0.42%,最新总市值为532.79亿元。该股当日开盘32.96元,最高33.62元,最低32.57元,成交额达4.36亿元,换手率为1.0%。近日,四川科伦药业股份有限公司公告其控股子公司科伦博泰研发的芦康沙妥珠单抗在2026年欧洲肺癌大会上公布OptiTROP-Lung03研究的总生存期最终分析结果。该研究显示,相较于多西他赛,芦康沙妥珠单抗在经治EGFR突变非小细胞肺癌患者中表现出显著生存获益,中位OS达20.0个月,HR为0.45。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800040648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","002422","BK0239","LU2148510915.USD","LU1979443071.USD","BK0060","LU1064130708.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618055516","title":"英硅智能与Liquid AI达成合作;氢溴酸他泽司他片被召回","url":"https://stock-news.laohu8.com/highlight/detail?id=2618055516","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618055516?lang=zh_cn&edition=full","pubTime":"2026-03-10 08:03","pubTimestamp":1773101006,"startTime":"0","endTime":"0","summary":"政策动向氢溴酸他泽司他片启动召回程序国家医保局3月9日消息显示,和黄医药(中国)有限公司发布公告,对其授权引进产品氢溴酸他泽司他片(商品名:达唯珂)启动撤市及产品召回程序。据此,自2026年3月9日起,撤销氢溴酸他泽司他片在全国各省级医药采购平台挂网,并根据企业申请,将氢溴酸他泽司他片移出《商业健康保险创新药品目录(2025年)》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103666774021.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103666774021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK0239","LU1781817850.SGD","LU2097828805.USD","BK4160","LU1328615791.USD","BK0012","TSLP","LU2488822045.USD","LU2580892862.HKD","LU2097828557.USD","LU2580892789.USD","LU2495084118.USD","GIPR","LU2097828631.EUR","LU1997245094.SGD","BK0060","LU1064131003.USD","LU1655091616.SGD","BK0187","LU1146622755.USD","LU2097828714.EUR","LU2289578879.USD","BK0028","002422","LU1934453819.USD","LU1979443071.USD","BK0188","LU2148510915.USD","LU0405327494.USD","LU1969619763.USD","BK0183","LU1820825898.SGD","LU1064130708.USD","688621","BK0216","600276","BK0096","LU1255011170.USD","LU1580142542.USD","LU2097828474.EUR","LU1997244956.HKD","LU2328871848.SGD","LU0405327148.USD","LU1997245177.USD","600196","IND","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618664977","title":"科伦药业(002422.SZ):SKB575新药临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618664977","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618664977?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:04","pubTimestamp":1773047075,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦药业(002422.SZ)公告,公司近日获悉,公司控股子公司四川科伦博泰生物医药股份有限公司(简称“科伦博泰”)与和铂医药控股有限公司(简称“和铂医药”)合作研发的靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体(bsAb)SKB575(亦称HBM7575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准,用于治疗特应性皮炎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦药业(002422.SZ):SKB575新药临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1979443071.USD","BK0239","LU1064130708.USD","002422","LU1934453819.USD","LU1064131003.USD","BK0060","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617683495","title":"3月6日科伦药业涨7.93%,中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683495?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:27","pubTimestamp":1772785676,"startTime":"0","endTime":"0","summary":"证券之星消息,3月6日科伦药业涨7.93%,收盘报32.68元,换手率1.87%,成交量24.36万手,成交额7.78亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共74家,其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元,最新净值1.6726,较上一交易日上涨0.9%,近一年上涨6.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600025963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","BK0060","LU1064130708.USD","LU2148510915.USD","159760","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617557198","title":"股市必读:科伦药业(002422)3月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617557198?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:02","pubTimestamp":1772643739,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘,科伦药业报收于29.22元,下跌1.02%,换手率0.63%,成交量8.28万手,成交额2.43亿元。公司公告汇总2026年度第二期科技创新债券发行结果的公告四川科伦药业股份有限公司2026年度第二期科技创新债券已于2026年3月2日发行,募集资金于3月3日到账。本期债券简称“26科伦 SCP002(科创债)”,代码012680513,期限269日,起息日为2026年3月3日,兑付日为2026年11月27日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500000585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","002422","BK0060","LU1064131003.USD","LU2148510915.USD","LU1979443071.USD","LU1934453819.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616553293","title":"科伦药业(002422)发布关于首次回购公司股份的公告,3月2日股价下跌1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616553293","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616553293?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:29","pubTimestamp":1772461759,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,科伦药业报收于30.2元,较前一交易日下跌1.11%,最新总市值为482.61亿元。该股当日开盘30.21元,最高30.45元,最低29.51元,成交额达4.56亿元,换手率为1.17%。近日,四川科伦药业股份有限公司发布《关于首次回购公司股份的公告》。本次回购符合相关法律法规及公司已披露的回购方案的规定。公司后续将根据市场情况继续实施回购计划,并按规定履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200039837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU1979443071.USD","BK0239","002422","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614032360","title":"股市必读:科伦药业(002422)2月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2614032360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614032360?lang=zh_cn&edition=full","pubTime":"2026-02-26 01:04","pubTimestamp":1772039052,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,科伦药业报收于31.02元,上涨0.06%,换手率0.57%,成交量7.51万手,成交额2.33亿元。当日关注点来自交易信息汇总:2月25日主力资金净流入1197.21万元,游资资金同步净流入1242.9万元,显示市场资金积极介入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600000586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","BK0060","LU1979443071.USD","LU1934453819.USD","LU1064131003.USD","002422","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608551877","title":"科伦药业(002422)披露回购公司股份进展公告,2月3日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608551877","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608551877?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:27","pubTimestamp":1770128844,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘,科伦药业报收于30.4元,较前一交易日上涨0.86%,最新总市值为485.81亿元。该股当日开盘30.36元,最高30.48元,最低30.01元,成交额达2.35亿元,换手率为0.6%。近日,科伦药业发布《关于回购公司股份进展的公告》。截至2026年1月31日,公司尚未实施回购。公司将根据市场情况推进回购,并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1979443071.USD","002422","LU1064131003.USD","LU1064130708.USD","LU1934453819.USD","LU2148510915.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776270626363,"stockEarnings":[{"period":"1week","weight":0.0309},{"period":"1month","weight":0.0934},{"period":"3month","weight":0.0917},{"period":"6month","weight":0.0271},{"period":"1year","weight":0.0412},{"period":"ytd","weight":0.2164}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41048人(较上一季度减少6.85%)","perCapita":"31813股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159805万元","survey":" 四川科伦药业股份有限公司的主营业务是输液产品及非输液医药产品的研发、生产和销售。公司的主要产品是大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等。公司是国家大容量注射剂工程技术研究中心、生物靶向药物国家工程研究中心等多个国家创新平台。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}